AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27271264 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 30
Study 27271264 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 24048675 — intervention group
Group type: EXPERIMENTAL
Intervention: Company size >100
Number of subjects: 158
Study 24048675 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflicts with the supervisor
Number of subjects: 158
Study 24048675 — intervention group
Group type: EXPERIMENTAL
Intervention: Having >1 chronic diseases
Number of subjects: 158
Study 22360645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux dialyzers (polysulfone or triacetate) used in 4-hour hemodialysis sessions
Number of subjects: 165
Study 22360645 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 for predicting total phosphate removal
Number of subjects: 165
Study 22360645 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 for predicting total phosphate removal (noninvasive)
Number of subjects: 165
Study 22360645 — intervention group
Group type: EXPERIMENTAL
Intervention: Model validation
Number of subjects: 165
Study 20075849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides (LTP)
Number of subjects: 43
Study 20075849 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex+placebo)
Number of subjects: 43
Study 20075849 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and LTP (Ex+LTP)
Number of subjects: 43
Study 20075849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18707986 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg a day
Number of subjects: 25620
Study 18707986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg a day
Number of subjects: 25620
Study 18707986 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ramipril + telmisartan)
Number of subjects: 25620
Study 16393331 — intervention group
Group type: EXPERIMENTAL
Intervention: rMal d 1mut
Number of subjects: 14
Study 15758247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d for 4 weeks
Number of subjects: 64
Study 15758247 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 64
Study 11422263 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazolidinyl urea (IMID) patch test at concentrations from 0 to 600 microg/cm(2)
Number of subjects: 181
Study 11422263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazolidinyl urea (DU) patch test at concentrations from 0 to 600 microg/cm(2)
Number of subjects: 181
Study 11422263 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde patch test at 180 microg/cm(2)
Number of subjects: 181
Study 9404698 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-E (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, etoposide 100 mg/m2)
Number of subjects: 140
Study 9404698 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-T (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 2 mg, teniposide 60 mg/m2)
Number of subjects: 140
Study 9404698 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-E
Number of subjects: 140
Study 9404698 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV-T
Number of subjects: 140
Study 9404698 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (recombinant interferon-alpha-2b, 3 M.U., once a day for 9 months)
Number of subjects: 140
Study 9404698 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 140
Study 8487648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500-mg capsules)
Number of subjects: 7
Study 8487648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3552921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (24 to 480 mg per day)
Number of subjects: 38
Study 3552921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg long-acting per day)
Number of subjects: 38
Study 3552921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31076857 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined 25(OH)D for risk of type 2 diabetes
Number of subjects: 10655
Study 31076857 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined 25(OH)D for risk of prediabetes
Number of subjects: 10655
Study 31076857 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined diabetes for 25(OH)D
Number of subjects: 10655
Study 31076857 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined prediabetes for 25(OH)D
Number of subjects: 10655
Study 30314383 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 38
Study 30314383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 27544805 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein preload (40% protein, 0.4 CHO:fat)
Number of subjects: 36
Study 27544805 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein preload (40% protein, 3.6 CHO:fat)
Number of subjects: 36
Study 27544805 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate
Number of subjects: 36
Study 27544805 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine, leucine, isoleucine, lysine, α‐aminobutyric acid
Number of subjects: 36
Study 27544805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall amino acid profiles
Number of subjects: 36
Study 25025926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 63
Study 25025926 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 63
Study 21862334 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-vastus (MV) approach
Number of subjects: 1040
Study 21862334 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar (PP) approach
Number of subjects: 1040
Study 20385929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus of apelin‐36
Number of subjects: 50
Study 20385929 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infusions of (Pyr(1))apelin‐13 (30 to 300 nmol/min)
Number of subjects: 50
Study 20385929 — intervention group
Group type: COMPARATOR
Intervention: Acetylcholine
Number of subjects: 50
Study 20385929 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 50
Study 20385929 — intervention group
Group type: COMPARATOR
Intervention: (Pyr(1))apelin‐13
Number of subjects: 50
Study 17551726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy extracorporeal shock wave treatment (ESWT; 1,500 shocks at 18 kV, 0.22 mJ/mm(2) without local anaesthesia)
Number of subjects: 56
Study 17551726 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous tenotomy of the common extensor origin
Number of subjects: 56
Study 16899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-based immunosuppressive regimen
Number of subjects: 126
Study 16899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppressive regimen
Number of subjects: 126
Study 16899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Not treating subclinical acute rejection (SAR)
Number of subjects: 126
Study 16899517 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled individualized calcineurin inhibitor exposure
Number of subjects: 126
Study 14986815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low daily doses of IFN‐alpha2b (1.5 MU) 'consolidation therapy' for 1 year
Number of subjects: 236
Study 14986815 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 236
Study 10986437 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8799660 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate level physical activity
Number of subjects: 666
Study 8799660 — intervention group
Group type: EXPERIMENTAL
Intervention: High level physical activity
Number of subjects: 666
Study 8799660 — intervention group
Group type: COMPARATOR
Intervention: Low-level physical activity (reference group)
Number of subjects: 666
Study 1601137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield (IUD)
Number of subjects: 71
Study 1601137 — intervention group
Group type: COMPARATOR
Intervention: Case-control and cohort studies
Number of subjects: 71
Study 2413519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories, 50 mg twice daily
Number of subjects: 30
Study 2413519 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 30
Study 2413519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and Placebo
Number of subjects: 30
Study 31372803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (n=14)
Number of subjects: 45
Study 31372803 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load resistance training (n=15)
Number of subjects: 45
Study 31372803 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n=16)
Number of subjects: 45
Study 30328984 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy
Number of subjects: 124
Study 30328984 — intervention group
Group type: COMPARATOR
Intervention: Public intensive care units
Number of subjects: 124
Study 30328984 — intervention group
Group type: COMPARATOR
Intervention: Private intensive care units
Number of subjects: 124
Study 30328984 — intervention group
Group type: EXPERIMENTAL
Intervention: General approach to renal replacement therapy
Number of subjects: 124
Study 27251406 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cycling (INT, 4 × 30 s maximal sprints interspersed by 4 min passive recovery)
Number of subjects: 8
Study 27251406 — intervention group
Group type: COMPARATOR
Intervention: Continuous cycling (CON, 2 min continuous maximal sprint)
Number of subjects: 8
Study 25549483 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with reamberinum
Number of subjects: 60
Study 25549483 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with modified gelatin (Gelofusin)
Number of subjects: 60
Study 25549483 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with sodium chloride 0.9%
Number of subjects: 60
Study 25549483 — intervention group
Group type: COMPARATOR
Intervention: No infusion therapy
Number of subjects: 60
Study 23359968 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA and Fuzheng Huayu Capsule (FHC)
Number of subjects: 80
Study 23359968 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 80
Study 20407369 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRON RX-I (wrist monitor) with hand positioned on the opposite shoulder
Number of subjects: 200
Study 20407369 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRON RX-I (wrist monitor) with hand positioned on the opposite elbow
Number of subjects: 200
Study 20407369 — intervention group
Group type: COMPARATOR
Intervention: OMRON M4-I (arm monitor, gold standard)
Number of subjects: 200
Study 18991514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seed aqueous extract (0.375 mL/kg of 50 g% boiled extract)
Number of subjects: 40
Study 18991514 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study 16055807 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cognitive-behavioural therapy for patients in the early initial prodromal state
Number of subjects: 188
Study 16055807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptic amisulpride for patients in the late initial prodromal state
Number of subjects: 188
Study 16055807 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (control condition)
Number of subjects: 188
Study 12452756 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol combination therapy
Number of subjects: 0
Study 12452756 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids alone
Number of subjects: 0
Study 10027654 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 12.5 mg x kg(‐1)
Number of subjects: 12
Study 10027654 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 25 mg x kg(‐1)
Number of subjects: 12
Study 10027654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.03 mg x kg(‐1)
Number of subjects: 12
Study 10027654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7585492 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care personnel providing information
Number of subjects: 83
Study 7585492 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal communication from the physician
Number of subjects: 83
Study 7585492 — intervention group
Group type: EXPERIMENTAL
Intervention: Written material
Number of subjects: 83
Study 7585492 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses as an information source
Number of subjects: 83
Study 2265765 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 2265765 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7442534 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous physical exertion
Number of subjects: 35
Study 7442534 — intervention group
Group type: COMPARATOR
Intervention: Less strenuous physical exertion
Number of subjects: 35
Study 30852021 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate space allowance (MOD; 1.85 m2)
Number of subjects: 54
Study 30852021 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximized space allowance (MAX; 3.71 m2)
Number of subjects: 54
Study 30852021 — intervention group
Group type: COMPARATOR
Intervention: Conventional space allowance (CONV; 1.23 m2)
Number of subjects: 54
Study 28384521 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite scaffold (Group B)
Number of subjects: 26
Study 28384521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite granules (Group C)
Number of subjects: 26
Study 28384521 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (Group A)
Number of subjects: 26
Study 26327116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 303
Study 26327116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab plus laser combination therapy
Number of subjects: 303
Study 26327116 — intervention group
Group type: COMPARATOR
Intervention: Laser monotherapy
Number of subjects: 303
Study 24138699 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing for CT and NG infection
Number of subjects: 12
Study 24138699 — intervention group
Group type: COMPARATOR
Intervention: Current diagnostic guidelines
Number of subjects: 12
Study 21443536 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg
Number of subjects: 0
Study 21443536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21443536 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Practice Composite Score (DP-6)
Number of subjects: 0
Study 19733712 — intervention group
Group type: COMPARATOR
Intervention: Full drug-eluting stenting (full DES)
Number of subjects: 179
Study 19733712 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot drug-eluting stenting (spot DES)
Number of subjects: 179
Study 17762645 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation group (generalized transfer function)
Number of subjects: 93
Study 17762645 — intervention group
Group type: COMPARATOR
Intervention: Validation group (generalized transfer function)
Number of subjects: 93
Study 14752469 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected images
Number of subjects: 102
Study 14752469 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncorrected images
Number of subjects: 102
Study 11502527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin 200 mg
Number of subjects: 0
Study 11502527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin 400 mg
Number of subjects: 0
Study 11502527 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 0
Study 11502527 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study 10762102 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group (focused on positive issues about bone density screening)
Number of subjects: 90
Study 10762102 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative group (focused on negative issues about bone density screening)
Number of subjects: 90
Study 10762102 — intervention group
Group type: EXPERIMENTAL
Intervention: All-focusing group (focused on both positive and negative issues)
Number of subjects: 90
Study 10762102 — intervention group
Group type: COMPARATOR
Intervention: Control group (focused on issues relating to the common cold)
Number of subjects: 90
Study 8777381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) low-dose regimen starting with 45 mg/day, lowering dose thereafter
Number of subjects: 32
Study 8777381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) 60 mg/day + levothyroxine
Number of subjects: 32
Study 8777381 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) 30 mg/day + levothyroxine
Number of subjects: 32
Study 8777381 — intervention group
Group type: EXPERIMENTAL
Intervention: All MMI regimens
Number of subjects: 32
Study 1853688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 1.5 mg.ml‐1
Number of subjects: 60
Study 1853688 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1 mg.kg‐1
Number of subjects: 60
Study 6346833 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 18
Study 6346833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 18
Study 6346833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30039192 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention condition
Number of subjects: 80
Study 30039192 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention condition
Number of subjects: 80
Study 29429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum free DNA hTERT content in spinal cord injury patients (experimental group)
Number of subjects: 46
Study 29429253 — intervention group
Group type: COMPARATOR
Intervention: Disease control group (spinal fractures)
Number of subjects: 46
Study 29429253 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (healthy volunteers)
Number of subjects: 46
Study 29429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein content of TERT in spinal cord injury patients (experimental group)
Number of subjects: 46
Study 29429253 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface evoked potential (SEP) detection in spinal cord injury patients (experimental group)
Number of subjects: 46
Study 27123743 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) administered in 3 doses according to a 0, 1, 6 months schedule.
Number of subjects: 674
Study 24669794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (dopamine D2-like receptor agonist) during sleep
Number of subjects: 16
Study 24669794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22682949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Metformin
Number of subjects: 0
Study 22682949 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 20027029 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 38
Study 20027029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17564327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 17564327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0
Study 17564327 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 17564327 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 15742005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg daily for up to 4 years
Number of subjects: 1457
Study 15742005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1457
Study 15742005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 1457
Study 12438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation combined with low-tech rehabilitative exercise
Number of subjects: 191
Study 12438988 — intervention group
Group type: EXPERIMENTAL
Intervention: MedX rehabilitative exercise
Number of subjects: 191
Study 12438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation alone
Number of subjects: 191
Study 12438988 — intervention group
Group type: EXPERIMENTAL
Intervention: Two exercise groups (spinal manipulation combined with low-tech rehabilitative exercise and MedX rehabilitative exercise)
Number of subjects: 191
Study 10064664 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow feed advancement (15 cc/kg/d increments, 10-day schedule to full feeds)
Number of subjects: 185
Study 10064664 — intervention group
Group type: COMPARATOR
Intervention: Fast feed advancement (35 cc/kg/d increments, 5-day schedule to full feeds)
Number of subjects: 185
Study 10064664 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow feed advancement
Number of subjects: 185
Study 10064664 — intervention group
Group type: COMPARATOR
Intervention: Fast feed advancement
Number of subjects: 185
Study 7743796 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline administration
Number of subjects: 43
Study 7743796 — intervention group
Group type: EXPERIMENTAL
Intervention: Meibomian gland expression therapy
Number of subjects: 43
Study 7743796 — intervention group
Group type: COMPARATOR
Intervention: Ocular rosacea patients (n = 28)
Number of subjects: 43
Study 7743796 — intervention group
Group type: COMPARATOR
Intervention: Dermatologic rosacea patients (n = 15)
Number of subjects: 43
Study 2225367 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 780
Study 2225367 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study 30638154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance circuit-based training in hypoxia (HRChyp)
Number of subjects: 28